Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251221 · ClinicalTrials.gov registry record · Early Phase 1
Measuring the Neuroimmune Response to Alcohol
A Early Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT04251221: Completed Early Phase 1 study, sponsored by Yale University.
NCT04251221 is a Early Phase 1 study that has completed, run by Yale University. The registered enrollment target is 14 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04251221, a Early Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study uses positron emission tomography imaging of the 18-kDa translocator protein to measure the brain's immune response to alcohol.
Primary Outcome
This is the percent change in \[11C\]PBR28 distribution volume (V\_T) post-alcohol relative to baseline. This is calculated as \[V\_T(Post-Alcohol) - V\_T(Baseline)\]/V\_T(Baseline) As a percent change, it could range from -10% to 200%.
Interventions
- DRUG Oral Alcohol Challenge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2021-11-20 |
| Phase | Early Phase 1 |
What the finished NCT04251221 record still lists
NCT04251221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Oral Alcohol Challenge is the first listed.
NCT04251221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04251221 about?
NCT04251221 is a clinical study titled "Measuring the Neuroimmune Response to Alcohol". This study uses positron emission tomography imaging of the 18-kDa translocator protein to measure the brain's immune response to alcohol.
What is the current status of trial NCT04251221?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2019-06-20. Estimated completion is 2021-11-20.
What interventions are being tested in trial NCT04251221?
The interventions under investigation include: Oral Alcohol Challenge (DRUG).
Who is sponsoring clinical trial NCT04251221?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04251221's enrollment target sits among peer trials
14 1475th of 2000 higher than 498 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy